DiaMedica Therapeutics (DMAC) Total Current Liabilities (2017 - 2026)

DiaMedica Therapeutics has reported Total Current Liabilities for 10 years, with the latest figure at $5.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 23.22% year-over-year to $5.7 million; the trailing twelve-month figure through Mar 2026 stood at $5.7 million (up 23.22% YoY), and the FY2025 full-year result was $5.1 million, down 4.79% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $5.7 million, up from $5.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $5.7 million in Q1 2026, with the low at $1.4 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $3.3 million across 5 years, with a median of $2.8 million in 2023.
• The largest YoY upside for Total Current Liabilities was 98.02% in 2024 against a maximum downside of 7.0% in 2024.
• DiaMedica Therapeutics' Total Current Liabilities stood at $2.2 million in 2022, then grew by 28.51% to $2.8 million in 2023, then soared by 93.47% to $5.4 million in 2024, then declined by 4.79% to $5.1 million in 2025, then rose by 12.0% to $5.7 million in 2026.
• The last three Total Current Liabilities figures came in at $5.7 million (Q1 2026), $5.1 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.